antiviral news

Press Releases in the global landscape

Nov 27, 2024

New Data: The Most Promising Treatments for Long COVID

A collection of common and new medications is showing good results against the constellation of symptoms that individualize long COVID.

Nov 26, 2024

Prescriptions of Covid-19 drug Lagevrio are to be limited to 70 and older

The age threshold for prescribing the government-supplied Covid-19 treatment Lagevrio (molnupiravir) will be raised to 70 and older from the current 60 and older.

Nov 21, 2024

Promomed tests a drug’s effectiveness against COVID-19 and influenza

Promomed is currently evaluating the efficacy of a new medication in the fight against both COVID-19 and influenza.

Nov 20, 2024

Study provides more positive data for Paxlovid use in high-risk patients with COVID-19

Treatment with Paxlovid significantly reduced the duration and severity of SARS-CoV-2 infection among high-risk patients while also reducing health care utilization and severe outcomes, according to a study.

Nov 18, 2024

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo.

Nov 14, 2024

Xocova Price to Be Trimmed by 300 Yen after CEA; No Change for Mounjaro

Japan will trim the NHI price of Shionogi’s oral COVID-19 treatment Xocova (ensitrelvir) by some 300 yen in February next year under the cost-effectiveness assessment (CEA) scheme, a key reimbursement policy panel agreed on November 13.